SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma.
Xian-De LiuYan-Ting ZhangDaniel J McGrailXuesong ZhangTruong Nguyen Anh LamAnh HoangElshad HasanovGaniraju C ManyamChristine B PetersonHaifeng ZhuShwetha V KumarRehan AkbaniPatrick G PiliéNizar M TannirGuang PengEric JonaschPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
SETD2 loss and ATR inhibition synergize to promote cGAS signaling and enhance immune cell infiltration, providing a mechanistic rationale for the combination of ATR and checkpoint inhibition in RCC patients with SETD2 mutations.